Retrospective Analysis of the Initial Empirical Antibiotic Therapy Effectiveness for Community-Acquired Pneumonia in Young Individuals in Moscow Multidisciplinary Hospital

Despite the fact that the incidence of community-acquired pneumonia (CAP) among young people is significantly lower than among older patients, the frequency of hospitalizations for severe CAP among people under 45 years of age remains high. The effectiveness and duration of treatment directly depend on the rationally selected initial empirical antibacterial therapy (ABT).
The aim of the study is to analyze the factors influencing the effectiveness of initial empiric antibacterial therapy for CAP in young people in multidisciplinary medical institutions.
Materials and methods. The study was designed as a retrospective observational study; it analyzes 105 medical records of young patients with CAP admitted to one of the multidisciplinary hospitals in Moscow from 2017 to 2019.
Results. The empiric ceftriaxone + azithromycin ABT regimen (70% of all prescriptions) was ineffective in 13.7% of cases; monotherapy with ceftriaxone (13% of all prescriptions) was ineffective in 57% cases. Severe CAP, acute respiratory failure, systemic inflammatory response syndrome, and exudative pleurisy were diagnosed with significantly higher frequency in the group of patients with ineffective initial empirical ABT. There was no predominance of any comorbid pathology and Charlson Comorbidity Index in groups where the initial ABT was changed and in groups without a change in initial ABT. The microbiological spectrum of CAP pathogens did not significantly differ in young patients between groups with a changed initial empirical ABT and a group without changing initial ABT.
Conclusion. The reasons for the ineffectiveness of the initial empirical ABT could be such factors as: underestimation of the risk of the presence of multidrug-resistant pathogens; underestimation of the risk of viral genesis of CAP; underestimation of the severity of CAP, as well as the severity of CAP complications.

1. Sharma R., Sandrock C.E., Meehan J., Theriault N. Community-acquired bacterial pneumonia — changing epidemiology, resistance patterns, and newer antibiotics: spotlight on delafloxacin. Clin Drug Investig. 2020; 40 (10): 947–960. doi: 10.1007/s40261-020-00953-z.

2. World Health Organisation. The top 10 causes of death 2018. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.

3. Ticona J. H., Zaccone V. M., McFarlane I. M. Community-acquired pneumonia: a focused review. Am J Med Case Rep. 2021 ; 9 (1): 45–52. doi: 10.12691/ajmcr-9-1-12.

4. Han X., Liu X., Chen L. et al. Disease burden and prognostic factors for clinical failure in elderly community acquired pneumonia patients. BMC Infect Dis. 2020; 20 (1): 668. Published 2020 Sep 12. doi: 10.1186/s12879-020-05362-3.

5. Klapdor B., Ewig S., Pletz M. W., Rohde G., Schütte H., Schaberg T., Welte T., CAPNETZ Study Group. Community-acquired pneumonia in younger patients is an entity on its own. Eur Respir J. 2012 May; 39 (5): 1156–1161. doi: 10.1183/09031936.00110911.

6. Сидоренко С.В., Яковлев С.В., Спичак Т.В. и др. Стратегия и тактика рационального применения антимикробных средств в амбулаторной практике. Евразийские клинические рекомендации. Педиатрия (Приложение к журнулу Consilium Medicum). 2017; 1: 17–25. [Sidorenko S.V., Yakovlev S.V., Spichak T.V. et al. Strategy and tactics of the rational use of antimicrobial drugs in outpatient practice. Eurasian clinical guidelines. 2016. Pediatrics (Suppl. Consilium Medicum). 2017; 1: 17–25. (in Russian)]

7. Charlson M.E., Pompei P., Ales K.L. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40 (5): 373–383. doi: 10.1016/0021-9681(87)90171-8.

8. Зырянов С.К., Ченкуров М.С., Ивжиц М.А., Батечко Ю.А., Иванова E.Б., Якунина М.А. Исследование структуры сопутствующих заболеваний и этиологии внебольничной пневмонии у пациентов пожилого и старческого возраста. Клиническая микробиология и антимикробная химиотерапия. 2020; 22 (3): 242–248. https://doi.org/10.36488/cmac.2020.3.242-248. [Zyryanov S.K., Chenkurov M.S., Ivzhits M.A., Batechko Yu.A., Ivanova E.B., Yakunina M.A. Etiology of community-acquired pneumonia and prevalence of comorbidities in elderly patient population. Kliniceskaa Microbiologia I Antimicrobnaa Himioterapia. 2020; 22 (3): 242–248. https://doi.org/10.36488/cmac.2020.3.242-248. (in Russian)]

9. Carugati M., Aliberti S., Reyes L.F. et al. Microbiological testing of adults hospitalised with community–acquired pneumonia: an international study. ERJ Open Res. 2018; 4 (4): 00096. doi: 10.1183/23120541.00096-2018.

10. Aliberti S., Kaye K.S. The changing microbiologic epidemiology of community-acquired pneumonia. Postgrad Med. 2013; 125 (6): 31–42. doi: 10.3810/pgm.2013.11.2710.

11. Минздрав РФ. Клинические рекомендации «Внебольничная пневмония у взрослых». Год утверждения клинических рекомендаций (частота пересмотра): 2019 (пересмотр каждые 3 года). Российское респираторное общество. Межрегиональная ассоциация по клинической микробиологии и антимикробной химиотерапии. С.97. [Ministry of Health of the Russian Federation. Clinical guidelines «Community-acquired pneumonia in adults». Year of approval of the guidelines (revision frequency): 2019 (revision every 3 years). Russian Respiratory Society. Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy. 97 s. (in Russian)]

12. Sahuquillo-Arce J.M., Menéndez R., Méndez R., Amara-Elori I., Zalacain R., Capelastegui A. et al. Age-related risk factors for bacterial aetiology in community-acquired pneumonia. Respirology. 2016 Nov; 21 (8): 1472–1479. doi: 10.1111/resp.12851.

13. Villafuerte D., Aliberti S., Soni N.J. et al. Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community-acquired pneumonia. Respirology 2020; 25 (5): 543–551. doi: 10.1111/resp.13663. Epub 2019 Aug 5.

14. Kaysin A., Viera A.J. Community-Acquired Pneumonia in Adults: Diagnosis and Management. American family physician. 94 (9): 698–706.